Key result
LV collagen volume fraction >32% is linked to ~103% higher major adverse outcomes in DCM.
Why the study?
Does the extent of left ventricular collagen volume fraction (LV-CVF) assessed by left ventricular endomyocardial biopsy predict outcomes in patients with suspected dilated cardiomyopathy?
Cohort (n=524)
Does the extent of left ventricular collagen volume fraction (LV-CVF) assessed by left ventricular endomyocardial biopsy predict outcomes in patients with suspected dilated cardiomyopathy?
Hazard Ratio: 2.03 (95% CI 1.32–3.11)
p-value: p=<0.0001
No takes yet. Share an insight, caveat, or question.
Left ventricular endomyocardial biopsy is a safe procedure, and the quantification of collagen volume fraction provides independent prognostic value in patients with dilated cardiomyopathy.
Kayvanpour et al. (2025) conducted a cohort in Dilated cardiomyopathy (n=524). Left ventricular collagen volume fraction (LV-CVF) >32% vs. LV-CVF ≤32% was evaluated on Composite of heart failure-related death, sudden cardiac death, aborted sudden cardiac death, or cardiac transplantation (HR 2.03, 95% CI 1.32-3.11, p=<0.0001). Left ventricular collagen volume fraction >32% was significantly associated with a higher risk of the composite adverse outcome in patients with dilated cardiomyopathy (log-rank P<0.0001).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: